Crispr Therapeutics is trading at $56.66 with a -4.77% change (about 4.8% lower) during early trading on August 24, 2026, amid broader risk-off pressure on growth-oriented biotechnology shares.
- The move follows a 0.60% Nasdaq Composite decline and 0.30% S&P 500 decline, as investors weigh Iran sanctions, trade tensions, elevated oil prices, and high Treasury yields.
- No new company-specific announcement was identified; recent August 3 earnings and clinical updates remain supportive but do not explain today’s drop.